Salipro Biotech AB

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of multiple drug targets. The research and licence agreement will focus on advancing therapeutic solutions that target G protein-coupled receptors, ion channels, transporters and other integral membrane proteins in areas such as cardio-renal-metabolic diseases and mental health. Over 60% of all current drugs interact with membrane proteins embedded in the lipid membrane. However, these proteins are inherently unstable and challenging to investigate. The companies will use Salipro’s platform technology, which stabilises membrane proteins in their native forms, enabling them to be used in drug discovery programmes. BI will then conduct biophysical and structural studies on its pipeline targets enabled by the technology to identify potential therapeutic candidates. In exchange, Salipro will receive undisclosed research and option payments, and will be eligible for success-based milestone payments based on developmental results produced by BI under the collaboration. Salipro’s chief executive officer, Jens Frauenfeld, said: “We are excited to collaborate with the innovative teams at BI. By combining our Salipro platform technology with BI’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.” The partnership comes two months after BI said it would be gaining access to Synaffix’s antibody-drug conjugate (ADC) technology through a licensing agreement worth over $1.3bn. The deal covers “an agreed but undisclosed number of targets” and it aimed at broadening the ADC portfolio of Boehringer’s subsidiary, NBE Therapeutics. Lamine Mbow, global head of discovery research, BI, said at the time: “We are building a broad pipeline of ADCs addressing novel tumour target space to develop next-generation cancer treatments. “By combining our… expertise in cancer treatment development with Synaffix’s clinical-stage platform technology, we aim to accelerate the delivery of first-in-class cancer treatments to improve cancer patient outcomes.” BI also recently announced a new initiative aimed at detecting, diagnosing and treating chronic kidney disease (CKD) in the UK faster. The SPOT CKD (Screening, Prevention, Outreach and Treatment for Health Equity) initiative will seek to reduce health inequalities by improving early diagnosis and providing proactive care to slow the progression of the disease.

March 13, 2025 -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases. The partnership leverages Salipro Biotech’s proprietary Salipro® platform technology, which stabilises membrane proteins in their native forms, enabling their use in drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro®-technology to identify potential therapeutic candidates. Under the terms of the agreement, Salipro Biotech will receive research payments, option payments and is eligible for downstream success-based milestone payments based on developmental results generated by Boehringer Ingelheim under this collaboration. “We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” said Jens Frauenfeld, CEO of Salipro Biotech. “By combining our Salipro® platform technology with Boehringer Ingelheim’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.” Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilisation of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. The content above comes from the network. if any infringement, please contact us to modify.

The Swedish company aims to expedite drug discovery via in-house and collaborated pipelines. Credit: Tapati Rinchumrus/Shutterstock. Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The partnership is set to progress the discovery and development of new therapeutic solutions that target G protein-coupled receptors (GPCRs), transporters and ion channels, which are crucial in cardio-renal-metabolic and mental health diseases. Salipro platform technology will be leveraged in the partnership. This platform stabilises membrane proteins in their native states, facilitating their usage in drug discovery programmes. It brings together Salipro Biotech’s expertise and its platform technology for stabilising targets from the drug discovery programmes of Boehringer, enabling and expediting the development of new therapeutics. Boehringer plans to carry out structural and biophysical studies which include cryo-electron microscopy on its pipeline targets to detect potential candidates. Boehringer will provide Salipro with research and option payments. Salipro is qualified for success-based milestone payments contingent on the developmental outcomes produced by Boehringer under this partnership. Salipro Biotech CEO Jens Frauenfeld stated: “We are excited to collaborate with the innovative teams at Boehringer Ingelheim. “By combining our Salipro platform technology with Boehringer Ingelheim’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.” The Swedish company has established several research partnerships with pharmaceutical and biotech entities. It aims to expedite drug discovery via in-house and collaborated pipelines. In December 2024, the company announced the receipt of patents granted for its Salipro platform technology in both Australia and Singapore. It also facilitates drug discovery programmes, which include screening small molecule drugs, structure-based drug design and antibody discovery. In October 2023, Salipro Biotech entered a multi-target antibody research agreement with Icosagen, a biotech company.